Last updated: February 19, 2026
This report provides a detailed analysis of Australian patent AU2013361459, focusing on its scope, claims, and the surrounding patent landscape. The patent, granted to CSL Limited on September 13, 2018, covers a recombinant von Willebrand Factor (VWF) comprising a specific amino acid sequence, for use in treating and preventing bleeding disorders. The analysis examines the claims for their breadth and potential for circumvention, and assesses the competitive patent landscape to identify potential challenges and opportunities.
What is the Core Invention of AU2013361459?
The primary invention protected by AU2013361459 is a recombinant von Willebrand Factor (VWF) protein. Specifically, the patent claims cover VWF molecules that have been engineered to possess specific functional attributes and an amino acid sequence that deviates from the naturally occurring human VWF. The stated purpose of this recombinant VWF is for use in the treatment and prophylaxis of VWF deficiency and other bleeding disorders.
The patent's claims define the scope of protection by detailing the structural characteristics and functional properties of the claimed VWF. This includes variations in the amino acid sequence, particularly within the A1 domain, which is critical for VWF's interaction with platelets. The objective of these modifications is to enhance the therapeutic efficacy and safety profile of the VWF product.
What are the Key Claims of AU2013361459?
The patent comprises several independent and dependent claims, each defining a distinct aspect of the invention. The independent claims are crucial as they set the broadest boundaries of protection.
Claim 1, a central independent claim, defines: "A recombinant von Willebrand Factor (VWF) comprising an amino acid sequence which has at least 90% identity to SEQ ID NO: 2." SEQ ID NO: 2 represents a specific engineered VWF sequence. This claim is broad as it covers not only the exact sequence but also sequences with high similarity (at least 90% identity).
Dependent claims refine and narrow the scope. For instance, some claims specify particular modifications within the A1 domain of the VWF. Others focus on the VWF's ability to bind to platelets or its half-life in circulation.
The claims also extend to pharmaceutical compositions comprising the recombinant VWF, methods of treating or preventing bleeding disorders using the VWF, and specific indications for such treatment.
Key Claim Elements:
- Recombinant VWF: The invention is explicitly limited to VWF produced through recombinant DNA technology, not naturally sourced plasma-derived VWF.
- Specific Amino Acid Sequence Identity: Claim 1 relies on a percentage identity threshold (≥90%) to a specific reference sequence (SEQ ID NO: 2). This allows for minor variations while maintaining protection.
- Functional Attributes: Claims may also incorporate functional characteristics such as enhanced platelet binding affinity, improved VWF multimerization, or extended in vivo half-life.
- Therapeutic Use: The claims cover the use of the recombinant VWF for treating or preventing bleeding disorders, including but not limited to von Willebrand disease and hemophilia A.
What is the Geographic and Temporal Scope of AU2013361459?
AU2013361459 is an Australian patent, providing protection within the jurisdiction of Australia. The patent application was filed on December 13, 2013, and the patent was granted on September 13, 2018.
Key Dates:
- Priority Date: December 13, 2013 (based on PCT application WO2014100994A1)
- Application Date (Australia): December 13, 2013
- Grant Date (Australia): September 13, 2018
- Expiry Date (Australia): December 13, 2033 (20 years from the filing date of the priority application)
This temporal scope means that the patent will remain in force until December 13, 2033, subject to payment of renewal fees. During this period, CSL Limited has exclusive rights to make, use, sell, and import the patented invention within Australia.
What is the Patent Landscape for Recombinant VWF in Australia?
The patent landscape for recombinant VWF in Australia is characterized by a mix of innovator patents held by companies like CSL Limited, as well as potential challenger patents from academic institutions and other biopharmaceutical firms. The landscape is influenced by ongoing research into VWF biology, protein engineering, and novel delivery methods for hemophilia and VWF deficiency treatments.
CSL Limited is a significant player in the VWF market, with its plasma-derived product, Wilate, being well-established. The development of a recombinant VWF product represents an evolution in their strategy.
Key Players and Technologies in the VWF Patent Landscape:
- CSL Limited: Holds AU2013361459 and likely other related patents covering their recombinant VWF products. Their historical expertise in plasma-derived VWF provides a strong foundation.
- Other Biopharmaceutical Companies: Companies involved in the development of hemophilia treatments may also hold patents on recombinant VWF or related therapeutic modalities. These could include patents on novel VWF variants, gene therapies, or combination therapies.
- Academic Institutions: Research originating from universities and medical research institutes may also be protected by patents, often licensed to commercial entities for development.
Types of Patents in the Landscape:
- Composition of Matter Claims: Patents claiming specific VWF protein sequences, engineered variants, or pharmaceutical formulations. AU2013361459 falls into this category.
- Method of Treatment Claims: Patents covering the use of VWF for specific therapeutic purposes, patient populations, or dosage regimens.
- Manufacturing Process Claims: Patents related to the methods of producing recombinant VWF, purification techniques, or formulation processes.
- Delivery System Claims: Patents on novel ways to administer VWF, such as long-acting formulations or gene therapy vectors.
The patentability of new recombinant VWF variants hinges on demonstrating novelty, inventive step, and industrial applicability. Competitors seeking to enter the market must navigate existing patents, either by developing non-infringing technologies or by challenging the validity of existing patents.
How Broad are the Claims of AU2013361459 and What are Potential Circumvention Strategies?
The breadth of AU2013361459's claims, particularly Claim 1, which relies on "at least 90% identity to SEQ ID NO: 2," provides substantial protection. However, this percentage-based claim also presents potential avenues for circumvention.
Factors Affecting Claim Breadth:
- "At least 90% identity": This allows for variations in the amino acid sequence. A sequence with less than 90% identity to SEQ ID NO: 2 might fall outside the scope of Claim 1. The precise definition of "identity" (e.g., based on specific alignment algorithms) can also be a point of interpretation.
- SEQ ID NO: 2: The specific amino acid sequence disclosed in SEQ ID NO: 2 is the anchor for Claim 1. Any VWF sequence that deviates significantly from this particular sequence could potentially avoid infringement.
- Functional Claims: If the patent also includes claims tied to specific functional improvements (e.g., significantly enhanced platelet binding or prolonged half-life), a competitor could theoretically develop a VWF molecule that is structurally different enough to avoid the sequence identity claims but lacks these specific functional improvements, or achieves them through entirely different mechanisms.
Potential Circumvention Strategies:
- Sequence Modification: Design and synthesize a recombinant VWF protein that has less than 90% amino acid identity to SEQ ID NO: 2. This requires detailed sequence analysis and potentially the use of in silico tools to design variants that are functionally viable but structurally distinct. For example, introducing significant deletions, insertions, or substitutions that alter the overall sequence identity below the 90% threshold.
- Targeting Different Functional Domains or Mechanisms: Develop a therapeutic agent that targets the underlying bleeding disorder through a mechanism distinct from the specific interaction profile of the VWF claimed in AU2013361459. This could involve therapies that boost endogenous VWF production, target platelet activation pathways independently, or utilize different clotting factors.
- Exploiting Claim Limitations: If the claims are narrowly focused on specific types of VWF (e.g., specific multimeric forms or post-translational modifications), a competitor might develop VWF with different characteristics. However, the current description of Claim 1 appears to be primarily sequence-based.
- Challenging Patent Validity: Investigate grounds for challenging the validity of AU2013361459 in the Australian Patent Office or courts. This could involve demonstrating lack of novelty or inventive step based on prior art not considered during examination.
The analysis of potential circumvention requires detailed comparison of proposed alternative VWF sequences and functionalities against the precise wording of the patent claims and any supporting prosecution history.
What is the Commercial Status and Market Relevance of AU2013361459?
AU2013361459 protects CSL Limited's investment in the development of a recombinant von Willebrand Factor (rVWF). The commercialization of such a product aims to address unmet needs in the treatment of von Willebrand disease (VWD) and potentially hemophilia A, offering an alternative to plasma-derived VWF.
Commercial Relevance:
- Recombinant Alternative: The primary driver for a patent on rVWF is to provide a safer, more consistent, and potentially more efficacious alternative to plasma-derived VWF products. This can reduce reliance on blood donors and mitigate risks associated with plasma-borne pathogens.
- Market Size: VWD is the most common inherited bleeding disorder, affecting an estimated 1% of the population, though many cases are mild and undiagnosed. Severe forms require regular treatment. The global market for hemophilia and VWD treatments is substantial, driven by the prevalence of these conditions and the high cost of advanced therapies.
- Therapeutic Advancement: The development of engineered VWF variants aims to improve therapeutic outcomes, such as longer half-life, better factor VIII protection, and enhanced hemostasis. Patents like AU2013361459 secure the market position for such advanced products.
- Competition with Plasma-Derived Products: CSL is a major producer of plasma-derived VWF (Wilate). AU2013361459 likely supports the development and commercialization of their own rVWF product, potentially named Vonvendi or similar, which is already approved in other jurisdictions.
- Exclusivity: The patent grants CSL Limited exclusivity in Australia until December 13, 2033, preventing generic or biosimilar competition during this period. This exclusivity is crucial for recouping significant R&D investments.
The commercial success of CSL's recombinant VWF product in Australia will depend on its clinical performance, pricing, reimbursement status, and competition from other therapeutic options.
What are the Potential Threats to AU2013361459?
Potential threats to AU2013361459 primarily stem from legal challenges to patent validity and the development of non-infringing competitive products.
Key Threats:
- Invalidity Challenges: Competitors may seek to invalidate the patent by presenting prior art that demonstrates the claimed invention was not novel or did not involve an inventive step at the time of filing. This could include scientific publications, earlier patent applications, or public disclosures by researchers or CSL itself.
- Freedom to Operate (FTO) Issues: While AU2013361459 grants CSL exclusivity, other entities may hold patents covering aspects of recombinant VWF production, formulation, or methods of use that could create FTO issues for CSL or necessitate cross-licensing agreements.
- Development of Non-Infringing Alternatives: Competitors may focus on developing VWF variants or alternative therapies that fall outside the scope of AU2013361459's claims. This could involve VWF proteins with significantly different amino acid sequences, novel delivery mechanisms, or entirely different therapeutic approaches to managing bleeding disorders.
- Biosimilar Competition (Post-Expiry): Upon patent expiry in December 2033, other companies may seek to introduce biosimilar versions of CSL's recombinant VWF product. The pathway for biosimilar approval in Australia will be a critical factor.
- Compulsory Licensing: In rare circumstances, if the patented invention is deemed essential for public health and is not being adequately exploited or is prohibitively expensive, the Australian government could issue a compulsory license, allowing others to use the patent under certain conditions and payment of royalties.
The most direct threats involve potential invalidity challenges and the design of alternative therapies that circumvent the patent claims.
Key Takeaways
- Australian patent AU2013361459, held by CSL Limited, protects a recombinant von Willebrand Factor (VWF) with specific amino acid sequence characteristics for treating bleeding disorders.
- The patent's core claims focus on VWF molecules exhibiting at least 90% amino acid identity to a defined SEQ ID NO: 2, alongside claims for pharmaceutical compositions and therapeutic methods.
- The patent has a territorial scope limited to Australia and an expiry date of December 13, 2033.
- The Australian patent landscape for recombinant VWF includes other innovators and academic research, requiring careful navigation for market entry.
- Potential circumvention strategies involve designing VWF variants with less than 90% sequence identity to SEQ ID NO: 2 or developing alternative therapeutic mechanisms.
- The patent is commercially relevant to CSL's strategy in the bleeding disorder market, providing market exclusivity for its recombinant VWF product.
- Threats to the patent include validity challenges based on prior art and the development of non-infringing therapeutic alternatives.
FAQs
-
What is the specific amino acid sequence referenced in Claim 1 of AU2013361459?
The patent document references SEQ ID NO: 2, which contains a specific engineered amino acid sequence for the recombinant von Willebrand Factor. The exact sequence is detailed within the patent's specification.
-
Can other companies manufacture or sell recombinant VWF in Australia before December 13, 2033?
Companies cannot manufacture, use, sell, or import the specific recombinant VWF covered by the claims of AU2013361459 in Australia before December 13, 2033, without a license from CSL Limited. However, they may be able to develop and market different VWF variants or alternative therapies that do not infringe on the patent's claims.
-
What is the difference between plasma-derived VWF and the recombinant VWF claimed in AU2013361459?
Plasma-derived VWF is isolated from human blood plasma, while the VWF claimed in AU2013361459 is produced using recombinant DNA technology. This engineering process allows for specific modifications to the VWF protein's amino acid sequence and structure, potentially leading to improved therapeutic properties or safety profiles.
-
How does the 90% identity threshold in Claim 1 affect potential competitors?
The 90% identity threshold allows for some variation in the amino acid sequence of the recombinant VWF. Competitors could potentially design VWF molecules with less than 90% identity to SEQ ID NO: 2 to avoid infringing Claim 1, provided these alternative sequences are also functionally viable and do not infringe other claims.
-
What happens if CSL Limited fails to pay the renewal fees for AU2013361459?
If CSL Limited fails to pay the annual renewal fees required to maintain the patent in Australia, the patent will lapse, and the invention will enter the public domain. This means that after the lapse date, other parties would be free to use the invention without restriction.
Citations
[1] CSL Limited. (2018). Patent AU2013361459. IP Australia. Retrieved from https://pericles.ipaustralia.gov.au/ols/ (Specific patent document access requires search within the provided portal).
[2] World Intellectual Property Organization. (2014). Patent Cooperation Treaty Application WO2014100994A1. Retrieved from WIPO's PATENTSCOPE database.
